DeviceTalks Interviews Dr. Shane Farritor and Dr. Piet Hinoul

We're excited to present the DeviceTalks podcast, "Extending a Surgeon's Reach into Space with Virtual Incision's Miniaturization and Remote Tech.” Host Tom Salemi sits down with Dr. Shane Farritor and Dr. Piet Hinoul from Virtual Incision Corporation (VIC) to discuss the launch of MIRA into space. This is the description of the podcast:

On Feb. 16, six surgeons successfully directed Virtual Incision’s spaceMira robotic surgery to perform “surgery” on the International Space Station. Instead of human tissue, the robotic arms cut rubber bands and other tissue like substitutes over 200 miles away from the surgeons. The exercise demonstrated the potential for remote-controlled robotic surgery. 

In this talk we’ll learn how the two-pound surgical robotic system was built and what this achievement could mean for future designs.

Note, the site does require registration to access the 59 minute podcast.

Shared by Tyler Stowater, board member of Virtual Incision Corporation.

Virtual Incision’s MIRA Surgical System to be Featured Among Elite AI-Enabled Innovations at NVIDIA GTC

Company To Showcase What is On Horizon For Miniaturized Robotic-Assisted Surgery and AI

LINCOLN, Neb. — March 18, 2024 — Virtual Incision Corporation, the developer of the MIRA Surgical System (MIRA), today announced the company will showcase MIRA at NVIDIA GTC. The global AI conference is focused on exploring what’s next in AI, computer graphics, data science, machine learning, and autonomous machines across industries. Virtual Incision will be featured in booth 1332 at the Healthcare Pavilion located inside the Expo Hall. The event will take place March 18–21, 2024 in San Jose, Calif.

During the conference, attendees will have the opportunity to perform a series of simulated surgical tasks with MIRA, the world’s first miniaturized robotic-assisted surgery (miniRAS) platform. The system utilizes the NVIDIA Jetson platform to collect, convert, and enhance visual data from MIRA’s integrated articulating camera. In addition, Virtual Incision will show examples of how Jetson can be used in future iterations of MIRA to enable capabilities such as low-latency remote surgery, intra-procedure AI-enhanced visualization, and post-procedure data analysis.

Read the rest of the press release on VIC’s website or view a PDF archive copy of the story here.

Shared by Tyler Stowater, board member of Virtual Incision Corporation.

Virtual Incision Receives FDA Authorization for the MIRA Surgical System as the First Miniaturized Robotic-Assisted Surgery Device

-New category challenges industry standards in soft tissue robotic-assisted surgery and has the potential to expand access to minimally invasive care

-De Novo premarket review pathway establishes initial indication for adults undergoing colectomy procedures and lays the foundation for expansion into other abdominal procedures

LINCOLN, Neb. — February 24, 2024 — Virtual Incision Corporation announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization of the MIRA™ Surgical System (MIRA), the world’s first miniaturized robotic-assisted surgery (miniRAS) device, for use in adults undergoing colectomy procedures. The device was submitted via the FDA’s De Novo Classification process, a rigorous pathway designed to classify novel medical devices with no current legally marketed predicate. FDA authorization was based in part on findings from the company’s U.S. Investigational Device Exemption (IDE) clinical study. The announcement was made by Virtual Incision’s president and chief executive officer, John Murphy, at the SAGES 5th Annual Next Big Thing Innovation Weekend in Houston.

“Today marks a turning point in surgical robotics as we have hit a significant milestone in making miniaturized robotic surgery a reality,” said John Murphy. “For more than a decade, our team has been dedicated to our core mission of making every operating room robot-ready. I’m incredibly proud to see our efforts come to fruition. We extend our gratitude to the FDA for its thoughtful review of MIRA’s technology and our clinical evidence. Whether as a complement to the existing mainframes or as a stand-alone platform, miniaturization has the potential to accelerate the adoption of robotic-assisted surgery.”

You can read the remainder of the press release on Virtual Incision’s website by clicking here, or view a PDF copy of the press release.

Shared by Tyler Stowater, board member of Virtual Incision Corporation

Virtual Incision’s Miniaturized Surgical Robot En Route to the International Space Station for Testing of Long-Range Remote Capabilities

Zerigo Health Appoints Eric Zerneke as New Chief Growth Officer to Expand Commercialization Efforts

Amazon Health Services alum brings 25 years of experience to fast-growing digital health company

SAN DIEGO — FEB 6, 2024 - Zerigo Health, a digital health platform for the home treatment of chronic skin conditions, including psoriasis and eczema, today announced the appointment of Eric Zerneke as the company’s Chief Growth Officer.

Click here to read the rest of the press release on Zerigo’s site, or click here to view it as a PDF.

Shared by Drew Doshier, board observer of Zerigo Health

Sydnexis Welcomes Erin Horn as Vice President, Head of Market Access

January 19,2023 – Sydnexis, Inc. (www.sydnexis.com), a clinical stage biopharmaceutical company focused on the treatment of progressive myopia in children and minimizing the risk of associated co-morbidities, is excited to announce the appointment of Erin Horn as its Vice President, Head of Market Access.  With a strong and diverse track record of commercial success in traditional and specialty ophthalmic pharmaceuticals, Erin will provide her market access, launch expertise, and commercial leadership to Sydnexis’ ongoing expansion and growth.

Erin will lead Sydnexis’ market access, pricing, contracting, and go-to-market strategies.  With 25 years of industry experience, Erin brings a wealth of knowledge in leading ophthalmic product launches and building successful brands and teams.

“We are thrilled that Erin has joined Sydnexis in pursuit of our mission. Erin brings a wealth of knowledge, expertise, and direct experience with market access customers and organizations that is unsurpassed in Ophthalmology. She is adynamic addition to the Sydnexis leadership team and we are extremely excited for her future success,” said Nick Ruth, Chief Commercial Officer at Sydnexis.

Read the rest of the press release here on Sydnexis’ site or a PDF copy of the story by clicking here.

SoundHound AI to Acquire SYNQ3 to Expand Its AI Customer Service Solutions and Create the Largest Voice AI Provider for Restaurants

Merger will create a new AI market leader with over 10,000 restaurant locations and best-in-class voice AI solutions

SANTA CLARA, Calif., December 07, 2023 – SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice artificial intelligence, today announced a definitive merger agreement to acquire SYNQ3 Restaurant Solutions, a leading provider of voice AI and other technology solutions to the restaurant industry.

The deal will make SoundHound the preeminent U.S. provider of voice AI for restaurants, significantly extending its market reach by an order of magnitude to over 10,000 signed locations and accelerating the deployment of leading-edge generative AI capabilities to the industry. SYNQ3 will add large brands spanning drive thru, fast casual, casual segments, and convenience stores to SoundHound’s fast growing customer base – bringing the total to more than 25 national and multinational chains.

The highly complementary businesses will match nearly two decades of SoundHound AI innovation with decades of SYNQ3 industry expertise and established relationships. The SYNQ3 team brings deep restaurant sales, product, and customer service experience with an increasing focus on AI. Seasoned executive talent like CEO and Co-Founder Steve Bigari, a former McDonald’s operator, will strengthen SoundHound AI’s leadership as the company moves to rapidly roll out its best-in-class proprietary AI solutions to restaurants across the U.S. and beyond.

Click here to read the rest of the release posted by SoundHound AI or click here to see a PDF of the press release.

Shared by Tyler Stowater, board member of SYNQ3 Restaurant Solutions.

ORASIS PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF QLOSI™ (PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION) 0.4% FOR THE TREATMENT OF PRESBYOPIA

QLOSI™ is a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials

Ponte Vedra, FL, October 18, 2023 – Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced that the U.S. Food and Drug Administration (FDA) has approved QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. QLOSI is expected to be commercially available in the U.S. in the first half of 2024.

“The FDA approval of QLOSI marks a tremendous milestone for Orasis as we continue our mission to provide a flexible treatment option for the millions of people in the U.S. living with presbyopia, or blurry near vision,” said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals. “I am grateful to the Orasis team, our strategic partners, clinical investigators, and patients who participated in our clinical trials, all of whom made this achievement possible.”

QLOSI (pronounced CLOH-see) is a prescription eye drop that can be used daily, or as needed, up to twice per day. QLOSI demonstrated efficacy 20 minutes after administration and can last up to 8 hours, as measured on day 15, to improve near vision without impacting distance or night vision. QLOSI is a preservative-free formulation of pilocarpine, an established eye care therapeutic, designed to achieve an optimal balance between efficacy, safety, and comfort.

“Patients experiencing age-related, blurry near vision are in need of flexible treatment options to manage their presbyopia in ways that work for them with fewer tradeoffs,” said Paul Karpecki, O.D., FAAO, Director, Cornea and External Disease, Kentucky Eye Institute, and Associate Professor, University of Pikeville, Kentucky College of Optometry. “In clinical trials, QLOSI demonstrated the optimal balance of efficacy, safety, and tolerability, and the FDA approval marks an exciting next step in being able to provide a new treatment for patients looking for a break from reading glasses or contact lenses.”

You can read the remainder of the press release here in the news page the Orasis website.

Shared by Tyler Stowater, board member of Orasis Pharmaceuticals.

Lentechs Announces Successful $6 Million Fundraise to Further Key Development Objectives

COLUMBUS, OH, Oct 17, 2023 – Lentechs, a clinical-stage ophthalmic medical device company developing a new generation of soft, suspended contact lens, designed to transform the treatment paradigm for presbyopia, today announced the closing of a successful fundraise to further key development objectives for its investigational contact lens for patients with presbyopia. The round was led by Vision Vestments LLC, with additional significant investments from JobsOhio Growth Capital Fund, Ohio Innovation Fund, Bluestem Capital, and Rev1 Ventures.

“This milestone signifies the strength and confidence in Lentechs and our APIOC®, a first-of-its-kind line of soft, suspended contact lens designed to deliver exceptional, glasses-like vision at all distances with the freedom of a contact lens. Proceeds will be utilized to finalize industry-leading manufacturing methods and additional randomized clinical trials that will test molded APIOC vs the leading multifocal contact lenses from each of the Big-4 contact lens manufacturers,” stated Mr. Robin G. Sears, CEO of Lentechs. “Thank you to all our Board of Directors members and the investors in our company for their continued support to improve visual outcomes for millions of people worldwide.”

Read the remainder of the press release by clicking here.

Shared by Tyler Stowater, board member of Lentechs.

Virtual Incision Extends Series C Round with Additional $30M Funding

Investment will accelerate advancements of the MIRA Surgical System

LINCOLN, Neb. – September 19, 2023Virtual Incision Corporation, the developer of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced a $30 million extension to its previous $46 million Series C financing. The round was led by current investors Bluestem Capital, Endeavour Vision, Baird Capital, cultivate(MD) Capital Funds, and PrairieGold Venture Partners, as well as new health-tech investors Arboretum Ventures and InVivium Capital.

Concurrent with the extension, Virtual Incision has appointed Tom Shehab, MD, managing partner from Arboretum Ventures, as a member of its board of directors, and Amy Kobe, general partner from InVivium Capital, as a board observer.

“We’re grateful for our investors – both existing and new – and are excited to build an even stronger medtech syndicate with the additions of Arboretum and InVivium,” said John Murphy, president and chief executive officer of Virtual Incision. “This financing, particularly in the current fundraising environment, is a significant affirmation of the promise Virtual Incision offers to both patients and shareholders.”

The $30 million funding extension will support the company’s operations well into 2025 as it seeks to disrupt the industry with miniaturized RAS (miniRAS). miniRAS aims to deliver the capabilities of traditional RAS systems through a form factor small enough to fit in a surgical tray. The compact, capable, and convenient design is uniquely positioned to expand RAS to the millions of patients who do not have access to the technology today.1

This funding comes on the heels of a series of significant milestones toward commercial readiness of the MIRA Surgical System. Earlier this year, Virtual Incision completed an Investigational Device Exemption (IDE) clinical study for MIRA’s use in bowel resection and announced that its De Novo request is under substantive review by the U.S. Food and Drug Administration (FDA). If granted marketing authorization, the company plans to initiate a limited launch of MIRA across select U.S. centers.

Read the rest of the press release on VIC’s site by clicking here. An archived PDF is available for download here.

Shared by Tyler Stowater, board member of Virtual Incision Corporation.

Casey's General Stores to Rollout SYNQ3 Restaurant Solution's Conversational AI Voice Ordering

Casey's, a visionary leader in the convenience store industry with over 2,500 stores, and the fifth-largest pizza chain in the US, is driving innovation forward by providing their guests with the voice ordering experience of the future. Through the implementation of Conversational AI across their stores, they've significantly enhanced their off-premise order-taking capabilities and operational efficiencies while radically enhancing the guest experience.

COLORADO SPRINGS, CO, September 6, 2023, Casey's General Stores, the third-largest convenience store and the fifth-largest pizza chain in the US, announced today the system-wide rollout of AVA (Automated Voice Assistant), a conversational AI voice ordering system that is powered by SYNQ3 Restaurant Solutions' technology: SYNQ Voice.

"We are excited to partner with SYNQ3 to give our team members more time to focus on our guests and operating our stores," said Sanjeev Satturu, Chief Information Officer, Casey's. "We are committed to reducing friction on our guests and team members by leveraging technology to simplify and streamline the ordering experience."

You can read the rest of the story here or open a PDF of the article.

Shared by Tyler Stowater, board member of SYNQ3 Restaurant Solutions.

Zerigo Health Appoints Lisa Rometty as Chief Executive Officer

Healthcare industry veteran, Rometty brings 25+ years of growth experience in Healthcare Technology and Services

SAN DIEGO, Aug. 7, 2023 /PRNewswire/ -- Zerigo Health, a digital health platform for the home treatment of chronic skin conditions, including psoriasis and eczema, announced today the appointment of Lisa Rometty as its new Chief Executive Officer. 

Rometty joins Zerigo after serving as President of CVS Kidney Care. In this role, she led the development of an innovative, personalized approach to kidney disease identification, care management, and home-first treatment. Previously, Lisa served as President of Global Client Solutions at Syneos Health, where she led the strategy and global expansion of the company's commercial partnerships and created new, innovative growth models.

"Lisa's go-to-market experience and success building home health ecosystems for consumers living with chronic conditions will be instrumental in scaling Zerigo," said Glen Tullman, Executive Chairman of Zerigo Health, Chief Executive Officer of Transcarent, and Managing Partner at 7wireVentures. "The market is searching for cost-effective alternatives to expensive biologics, and we are excited to have Lisa driving our mission to empower people living with chronic skin conditions with convenient, affordable, and personalized care."

Read the remainder of the press release here. Follow this link to see the newsroom of Zerigo.

Shared by Drew Doshier, board observer of Zerigo Health

Virtual Incision Has Achieved a Significant Milestone in its De Novo Request and is Closer to Potential Commercial Readiness

Virtual Incision Has Achieved a Significant Milestone in Its De Novo Request and is Closer to Potential Commercial Readiness 

Lincoln, Neb. – May 18, 2023 – Virtual Incision Corporation today announced its De Novo request was submitted and is under substantive review by the U.S. Food and Drug Administration (FDA). The submission seeks authorization to market ​the ​MIRA Surgical System for use in bowel resection procedures and comes on the heels of Virtual Incision’s completed Investigational Device Exemption (IDE) clinical study.

If granted, MIRA will become the first robotic-assisted surgery (RAS) device to obtain marketing authorization through the De Novo pathway for use in bowel resection procedures, making it a trailblazer in soft tissue robotics. Beyond granting Virtual Incision the ability to commercialize MIRA in the U.S. for its intended use, authorization may lay the foundations for expanded procedural indications, entry into international markets, additional instruments and accessories, and future generations of the surgical system.

“Throughout the history of RAS, only a few companies have managed to reach this significant milestone,” said John Murphy, president, and chief executive officer of Virtual Incision. “If we are successful with our submission, the FDA De Novo pathway will establish MIRA in a brand-new medical device category of miniaturized RAS. Our design is disruptive and highly differentiated among the current landscape of available and emerging technologies. We are proud of the data we collected, as it demonstrates the capabilities of MIRA in one of the most complex multi-quadrant abdominal procedures. We also observed many operational efficiencies that make the miniaturized approach so unique and potentially scalable to the millions of patients who could be candidates for RAS each year.”

If Virtual Incision obtains marketing authorization, the company plans to initiate a limited launch of MIRA in select centers across the U.S. These centers will aim to leverage the efficiencies created with MIRA to expand the number of patients they can treat with RAS. Their experiences will serve as best practices for the broader launch. In the longer term, the objective is to enable wide adoption in any healthcare facility for any patient undergoing abdominal surgery.

Click here to learn more and see the impressive team the company has assembled. A PDF of the press release is available here.

Shared by Tyler Stowater, board member of Virtual Incision Corporation.

One Millionth Patient Measured

As of today, one million patients have been measured on the Neurolens Measurement Device!

DALLAS, April 20, 2023 – Neurolens, a company commercializing innovative solutions to optimize vision, announced today that one million patients have been measured on the Neurolens Measurement Device, its cutting-edge eye tracking system that can identify eye misalignment as small as 0.01 Prism Diopters. Given the sharp acceleration in remote working and learning, optometrists have reported record numbers of patients experiencing the symptoms of eye misalignment such as headaches, eye strain and neck pain. Neurolenses have been proven to alleviate these symptoms for over 93% of patients.

“While we have grown tenfold in the past three years, the unmet patient need remains massive,” said Pierre Bertrand, Neurolens CEO. “Today we celebrate our one-millionth patient measured, a huge milestone for the organization. But with 80% of consumers experiencing symptoms of eyestrain according to The Vision Council’s recent report FocusedinSights: Digital Habits 2022, we are excited to continue bringing solutions to independent optometry to meet their needs. We are, first and foremost, in the business of patient outcomes.”

You can read the remainder of the article on Nueurolen’s newsroom or view this PDF copy of the story.

Shared by Steve Kirby, board member of Neurolens.

The Innovation Continues for Robotic-Assisted Surgery – Virtual Incision Completes FDA Investigational Device Exemption (IDE) Clinical Study for MIRA

Study results will be used to support the first FDA De Novo request for market authorization of the MIRA Surgical System as Virtual Incision makes progress towards its mission to expand RAS access

00:00 | 01:31

Lincoln, Neb. – February 22, 2023 – Virtual Incision Corporation, a medical device company spearheading the development of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced the completion of its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical study. The study was designed to evaluate the company’s MIRA Surgical System for use in bowel resection procedures. This is an important achievement towards bringing new technologies to hospitals and their surgical robotics programs regardless of the site of care.

The surgical cases were completed at three hospitals across the country. Patients who participated in the study were followed after their procedure to fulfill study requirements. The complete data will be correlated and submitted to the FDA as part of the company’s De Novo request for market authorization. Virtual Incision is the first RAS developer to complete a U.S. IDE study to support a De Novo request in bowel resection.

“The investigators are very encouraged by our experiences trialing the MIRA Surgical System,” said Michael A. Jobst, MD, colorectal surgeon. “Across the sites, we’ve seen MIRA efficiently integrate into existing RAS programs and witnessed how it is mobile enough for use in any operating room. Some sites have even completed multiple cases in a single day. We are eager to fulfill the clinical requirements of the study in hopes that MIRA can help expand RAS access to more patients in the future.”

There are 5 million Americans who undergo abdominal soft tissue procedures annually, however, more than 90 percent go without access to RAS. If authorized by the FDA, MIRA’s miniaturized, strong, and easy-to-use design could potentially increase the overall availability of RAS. It has the potential to integrate into any facility or operating room by serving as a complement to the existing mainframe RAS systems, or by expanding into new sites of care and geographies as a standalone. Virtual Incision aims to increase patient access through a clinically, operationally, and economically sound platform available to all providers.

“Completing MIRA’s IDE clinical study is a critical milestone in our journey to making RAS more accessible,” said John Murphy, president and chief executive officer of Virtual Incision. “Currently, less than 10 percent of the 90,000 operating rooms in the U.S. are equipped with mainframe RAS systems. Beyond the incredible progress of the industry pioneer, it’s still in the early days of the adoption of soft tissue surgical robotics. Our ultimate goal is to develop world-class miniature RAS devices with the required strength and dexterity to enable positive clinical outcomes for a broad range of procedure types.”

About the MIRA Surgical System MIRA is the world’s first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek design is planned to offer the benefits of RAS during bowel resection procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated mainframe room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a mainframe. With MIRA, every operating room is RAS-ready.

About Virtual Incision

Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over 200 patents and patent applications, the company is developing MIRA, the first-of-its-kind miniature RAS platform. Virtual Incision’s goal is to make every operating room RAS-ready. For more information, visit our website or follow us on LinkedIn and Twitter.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions.

Shared by Tyler Stowater, board member of Virtual Incision Corporation.

ORASIS PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR INVESTIGATIONAL NOVEL EYE DROP CANDIDATE, CSF-1, FOR THE TREATMENT OF PRESBYOPIA

- Presbyopia is the loss of ability to focus on near objects as a result of the natural aging process and affects more than 120 million people in the U.S.

- Phase 3 NEAR-1 and NEAR-2 clinical trials, involving over 600 patients, met primary and key secondary endpoints and serve as the basis for the submission

PONTE VEDRA, Fla., Jan. 3, 2023 - Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%).

"This NDA submission is a significant milestone for Orasis as we advance CSF-1 towards commercialization and achieving our goal of reshaping vision possibilities for patients," said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals. "With more than 120 million people in the U.S. affected, we look forward to working with the FDA during its review process to ultimately provide an alternative treatment option for patients seeking flexibility in managing their presbyopia."

The NDA is based on data from the Phase 3 NEAR-1 and NEAR-2 clinical trials, involving more than 600 patients, which evaluated the efficacy and safety of CSF-1. Both trials met their primary and key secondary endpoints on Day 8, achieving statistically significant 3-line or more gain in distance-corrected near visual acuity (DCNVA), and no loss of 1-line or more in distance visual acuity. The most common treatment-related adverse events of headache and instillation site pain occurred in only 6.8% and 5.8% of participants, respectively. Of all CSF-1 participants, only 2.6% reported moderate treatment-related adverse events. All other adverse events were mild.

Read the rest of the press release here on Orasis’ website or from a PDF here.

Shared by Tyler Stowater, board member of Orasis Pharmaceuticals.

Zerigo Health Announces Release of Eczema Solution

•Zerigo Health’s latest software release includes integrated, guideline-recommended phototherapy dosing protocols for the treatment of atopic dermatitis (commonly referred to as eczema), in addition to its existing protocols for psoriasis

•Evernorth, Cigna’s health services business, will offer Zerigo’s solution as part of a pilot program through its Digital Health Formulary and is the first to launch this new platform for both psoriasis and eczema

San Diego, CA – Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced the launch of a new software release which includes integration of the American Academy of Dermatology Guideline protocols for the treatment of eczema with narrowband ultraviolet B (NB-UVB) phototherapy.

Evernorth, Cigna Corporation's health services business, is the first to launch Zerigo's solution for both psoriasis and eczema, which will be offered as a pilot program through its Digital Health Formulary. The Evernorth Digital Health Formulary connects employers, insurers and patients with innovative, affordable, and evidence-based care that meets their broader health care needs. The pilot program will enable more people with chronic skin conditions to better manage their conditions.

Click here for the rest of the press release shared on Zerigo’s website or a PDF copy of the file here.

Shared by Drew Doshier, board observer of Zerigo Health